Results 11 to 20 of about 1,418,021 (124)
Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
Journal of Pain Research, 2015 Lynn R Webster,1 Michael D Smith,1 Cemal Unal,2 Andrew Finn3 1PRA Health Sciences, Salt Lake City, UT, USA; 2Biometrical Solutions LLC, Raleigh, NC, USA; 3BioDelivery Sciences International, Inc., Raleigh, NC, USA Abstract: In developmental research ...
Webster LR, Smith MD, Unal C, Finn A
doaj +1 more source
A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive [PDF]
Advances in Therapy, 2020 Lynn Webster, Erik Hansen
exaly +2 more sources
Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain [PDF]
Pain ManagementĐurđa Vukicevic +2 more
exaly +2 more sources
Academic Emergency Medicine, Volume 30, Issue 7, Page 709-720, July 2023., 2023 Abstract Background Opioid overdose deaths have disproportionately impacted Black and Hispanic populations, in part due to disparities in treatment access. Emergency departments (EDs) serve as a resource for patients with opioid use disorder (OUD), many of whom have difficulty accessing outpatient addiction programs. However, inequities in ED treatment
Wesley C. Holland +10 more
wiley +1 more source
Recent progress in orodispersible films‐mediated therapeutic applications: A review
MedComm – Biomaterials and Applications, Volume 2, Issue 2, June 2023., 2023 The current therapeutic applications of orodispersible films (ODFs) are delivered either locally or systemically for potential patients suffering from various diseases, including oral inflammation, cardiovascular diseases, pain disorders, nausea and vomiting, mood or mental disorders, erectile dysfunction and pulmonary diseases Abstract Orodispersible ...
Yu Tian +5 more
wiley +1 more source
Annual banned‐substance review—Analytical approaches in human sports drug testing 2021/2022–
Drug Testing and Analysis, Volume 15, Issue 1, Page 5-26, January 2023., 2023 Detection assays for drugs and methods of sports doping published between 2021 and 2022 are critically reviewed and evaluated in context with the Prohibited List 2022 as established by the World Anti‐Doping Agency. Abstract Also in 2021/2022, considerable efforts were invested into advancing human sports drug testing programs, recognizing and taking ...
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley +1 more source
Pharmaceutical Statistics, Volume 21, Issue 5, Page 1022-1036, September/October 2022., 2022 Abstract We develop a new modeling framework for jointly modeling first prescription times and the presence of risk‐mitigating behavior for prescription drugs using real‐world data. We are interested in active surveillance of clinical quality improvement programs, especially for drugs which enter the market under an FDA‐mandated Risk Evaluation and ...
Harris Butler +3 more
wiley +1 more source
Novel pharmaceutical dosage forms of analgesics [PDF]
Arhiv za farmaciju, 2018 Among novel pharmaceutical dosage forms of analgesics, whose number and diversity are continuously increasing over the past two decades, of particular importance are transdermal opioid analgesics (fentanyl, buprenorphine) for the treatment of chronic ...
Đekić Ljiljana, Primorac Marija
doaj +1 more source
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 42, Issue 5, Page 411-427, May 2022., 2022 Abstract Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual buprenorphine has been the standard of care for treating OUD, but its use in pain management is not as clearly defined.
Lauren A. Spreen +3 more
wiley +1 more source
Sublingual/Buccal buprenorphine and dental problems: a pharmacovigilance study
, 2023 The association between dental problems and sublingual/buccal buprenorphine is unclear. We conducted an analysis of dental adverse drug reactions reported with sublingual/buccal buprenorphine in VigiBase®, the pharmacovigilance database of the World ...
François Montastruc (119809) +5 more
core +1 more source